Compare Home Depot Inc (HD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Home Depot Inc trades at $329.58 (market cap $332.08B), while State Street SPDR S&P Biotech ETF trades at $153.21. The key difference: Home Depot Inc pays a 2.8% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Home Depot Inc nearer its low. Which is the better fit depends on your goals.
| HD | XBI | |
|---|---|---|
Market Cap | $332.08B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $423.42 | $164.28 |
52-Week Low | $297.51 | $85.16 |
Enterprise Value | $393.64B | — |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $331.77, down 2.1% today, with a bearish technical signal and mixed earnings history. The stock shows strong profitability with a 128.38% ROE and 8.41% net margin, but faces weakening profit margins and high valuation multiples. Recent news highlights institutional trading activity and concerns over housing market headwinds.
The outlook remains cautious due to technical weakness and margin pressure, though analyst consensus is bullish with a $370.59 price target. Key risks include rising mortgage rates impacting demand, while opportunities lie in Pro segment growth and dividend stability. The stock trades near support at $330, requiring monitoring of Q2 2026 earnings for direction.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
